IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.835
AS - Asia 10.377
EU - Europa 10.075
SA - Sud America 2.310
AF - Africa 991
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 19
Totale 49.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.800
SG - Singapore 5.333
CN - Cina 3.467
IE - Irlanda 2.646
IT - Italia 2.561
UA - Ucraina 2.395
BR - Brasile 1.992
CA - Canada 899
RU - Federazione Russa 703
CI - Costa d'Avorio 679
VN - Vietnam 424
SE - Svezia 327
DE - Germania 313
GB - Regno Unito 296
IN - India 282
KR - Corea 220
SN - Senegal 139
FI - Finlandia 117
AR - Argentina 116
FR - Francia 112
PL - Polonia 95
NL - Olanda 90
MX - Messico 89
CH - Svizzera 88
UZ - Uzbekistan 81
JP - Giappone 80
BD - Bangladesh 79
ZA - Sudafrica 68
EC - Ecuador 64
AT - Austria 61
TR - Turchia 58
ES - Italia 51
CZ - Repubblica Ceca 50
IQ - Iraq 49
HK - Hong Kong 48
BE - Belgio 47
GR - Grecia 44
LB - Libano 36
CO - Colombia 34
MA - Marocco 32
ID - Indonesia 30
VE - Venezuela 26
IR - Iran 25
PK - Pakistan 23
AU - Australia 20
PY - Paraguay 20
CL - Cile 19
IL - Israele 19
EU - Europa 18
SA - Arabia Saudita 17
JO - Giordania 15
KE - Kenya 15
PE - Perù 15
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
BO - Bolivia 13
EG - Egitto 13
LT - Lituania 13
BG - Bulgaria 12
AZ - Azerbaigian 11
DO - Repubblica Dominicana 11
NG - Nigeria 11
RS - Serbia 11
DZ - Algeria 10
KZ - Kazakistan 10
NO - Norvegia 9
RO - Romania 8
UY - Uruguay 8
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
JM - Giamaica 6
KW - Kuwait 6
NP - Nepal 6
TH - Thailandia 6
BH - Bahrain 5
CR - Costa Rica 5
MY - Malesia 5
OM - Oman 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
AL - Albania 4
BB - Barbados 4
HN - Honduras 3
LU - Lussemburgo 3
PA - Panama 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
HU - Ungheria 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NI - Nicaragua 2
SR - Suriname 2
SV - El Salvador 2
BA - Bosnia-Erzegovina 1
Totale 49.612
Salva come PNG Salva come JPEG
Città #
Dallas 5.108
Santa Clara 2.900
Singapore 2.722
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Boardman 1.117
Chicago 954
Catania 899
Nanjing 751
Ashburn 742
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 650
Houston 505
Hefei 501
Des Moines 423
Beijing 392
San Mateo 386
Los Angeles 312
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
Saint Petersburg 182
Shenyang 180
Hebei 176
São Paulo 172
Ottawa 148
Jiaxing 147
Dakar 138
Changsha 134
Florence 133
New York 125
Ho Chi Minh City 119
Tianjin 109
Rome 97
Grafing 96
Council Bluffs 94
Kochi 92
Dong Ket 87
Hanoi 81
Milan 81
Munich 71
Brooklyn 69
Tokyo 68
Buffalo 65
Palermo 65
Seattle 64
Moscow 62
Washington 58
Rio de Janeiro 57
Warsaw 57
Montreal 51
The Dalles 51
Boston 50
San Francisco 49
Stockholm 47
Columbus 46
Johannesburg 46
Belo Horizonte 45
Hangzhou 45
Hong Kong 45
Redondo Beach 44
Phoenix 43
Brussels 42
Turku 42
Chennai 39
Den Haag 39
Helsinki 38
Norwalk 37
Lappeenranta 36
Kunming 35
Poplar 34
Denver 33
Falls Church 32
Pune 32
Atlanta 31
Tashkent 31
Mumbai 30
Jinan 29
London 29
Bremen 28
Porto Alegre 28
Brasília 27
Mexico City 27
Curitiba 26
Ankara 25
Guangzhou 25
Campinas 23
Orem 23
Bari 22
Brno 22
Guayaquil 22
Messina 22
Quito 22
Ann Arbor 20
Liberty Lake 20
Totale 34.120
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 245
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 241
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 184
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 177
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 177
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 164
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 157
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 151
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 150
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 146
Il Rasario. Semeiotica medica 136
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 136
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 134
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 130
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 129
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 127
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 127
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 127
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 127
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 127
Hedgehog signaling pathways in multiple myeloma 122
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 120
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 120
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 119
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 117
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 117
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 117
A snapshot of asparaginase-induced liver insufficiency. 116
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 116
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 115
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 115
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 114
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 114
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 113
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 113
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 113
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 112
Acute pre-hepatic portal thrombosis: diagnosis and therapy 111
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 111
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 110
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 110
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 109
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 109
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 109
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 109
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 109
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 108
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 108
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 108
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 107
A case of high-risk AML in a patient with advanced systemic mastocytosis 106
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 106
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 105
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 105
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 105
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 105
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 104
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 104
Terapia del mieloma multiplo 103
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 103
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 103
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 102
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 102
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 102
Bone turnover markers in patients with type 1 Gaucher disease 102
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 102
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 101
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 101
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 101
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 100
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 100
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 100
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 100
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 100
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 99
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 99
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 99
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 99
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 99
Eventi avversi e trigger C12: Stroke in ospedale 99
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 98
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 95
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 95
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 95
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 94
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 94
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 93
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 93
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 93
Angiogenesis in acute myeloid leukemia 92
Cementoplasty in the management of painful extraspinal bone metastases: our experience 92
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 92
Acute myeloid leukemia in elderly patients. 91
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 91
Lymphoma of the cecum: a case report 90
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 90
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 90
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 90
The Heme Oxygenase System in Hematological Malignancies 90
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study 90
Totale 11.387
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.455
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.455
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.881 0 0 0 0 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202611.776 1.673 1.754 5.013 1.882 1.454 0 0 0 0 0 0 0
Totale 50.692